Wuhan Hiteck Biological Pharma Co., Ltd.

The company is a high-tech biopharmaceutical company with the goal of building an outstanding biopharmaceutical enterprise in China. It was listed on the Shenzhen Stock Exchange GEM on August 8, 2017. The main business is the production and sale of bioengineered products and freeze-dried powder needles; the import and export business of the company's products and technology. The company continues to work around the two main business lines of pharmaceutical manufacturing and R&D services. Its main business is the production and sale of macromolecular biopharmaceuticals, small-molecule chemicals, APIs and pharmaceutical intermediates, and also provides CRO, CMO and CDMO technical services for formulations and APIs to domestic and foreign pharmaceutical companies. The company's main products are biological products: nerve damage repair drugs, therapeutic biological products, chemical drugs, raw materials and intermediates, injectable rat nerve growth factors, injectable epneimine, injectable tedizolamide phosphate, antiviral drugs, etc. Company honors: Famous trademarks in Wuhan, top ten new private economy enterprises, top ten private economy enterprises, contract-honoring and trustworthy enterprises, enterprises with harmonious labor relationships, etc. It won honors such as “Top 50 Growth Companies in China's Pharmaceutical Industry in 2023" and “2023" and “China Pharmaceutical Industry Law-abiding and Honest Enterprise”.